Lotus Pharmaceutical Announces Day 1 Launch of Generic Enzalutamide in South Korea

Taipei, Taiwan, and Seoul, South Korea, 7 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that its wholly owned subsidiary Alvogen Korea has successfully completed the Day 1 commercial launch of its generic enzalutamide in South Korea, further strengthening the Company’s oncology and urology portfolio in one of Lotus’ key Asian markets.

Lotus’ enzalutamide, a generic version of Xtandi®, is an androgen receptor inhibitor used in treatment of certain patients with prostate cancer. The Day 1 launch expands treatment options for patients in South Korea by improving access to this important therapy.

Developed in-house by Lotus, its generic enzalutamide has been progressively launched across international markets since 2021. The product is now commercialised in more than 20 markets around the world, including South Korea, demonstrating the Company’s proven capabilities in developing and launching complex oncology products worldwide. According to IQVIA, the enzalutamide market in South Korea was valued at approximately KRW 53 billion, equivalent to approximately US$39 million, in the 12 months ended 1Q 2026, representing a four-year CAGR of 19.4%.

Petar Vazharov, Chief Executive Officer of Lotus, commented, “The Day 1 launch of enzalutamide in South Korea, one of our key markets in Asia, reflects our ability to execute efficiently. Following the recent addition of Uro-Vaxom®, Enzalutamide further strengthens our urology portfolio in South Korea as we continue to build our presence in this important therapeutic area. We remain committed to expanding patient access to high-quality medicines while continuing to strengthen our oncology portfolio across the region.”

Xtandi® and Uro-Vaxom® are registered trademarks. All other trademarks are the property of their respective owners.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.